decisionhealth Newsletters, Coder Pink Sheets - 2006 Issue 8 (August)
Gardasil: New $400-plus vaccine is here
Subscribe or sign in to view the full article.
Article Overview
This article explains the rollout of Gardasil, an FDA-approved HPV vaccine, and discusses how practices may approach payer coverage and patient billing for the vaccine series. It is aimed at pediatric, family medicine, and coding staff who need to understand the general reimbursement and contract considerations surrounding this newly available preventive service.
Why This Topic Matters
New vaccines can create immediate billing and contracting questions for physician practices, especially when product cost is high and payer coverage is still evolving. The article helps readers identify the service coding involved and understand why payer policy review matters before stocking the vaccine.
What You Will Learn
- The clinical and billing context for a newly approved HPV vaccine
- Why payer contract review is important when a high-cost vaccine enters the market
- Which broad practice settings are most likely to administer the vaccine
- General coverage and reimbursement considerations for vaccine procurement and administration
Who Should Read This
- Medical coders
- Biller/coding staff
- Pediatric practices
- Family medicine practices
- Practice managers
- Managed care staff
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com